Home
Search
Placeholder Banner
Letters, Testimony and Comments

BIO comments to USTR on the Agency’s 2023 Special 301 Review, January 30, 2023

January 31, 2023
Download Full Comments Below
BIO_2023%20Special%20301_Review_Comment%20.pdf
Download
Discover More
FTC HSR Comments
BIO Comments to FTC on…
Comments on Revised HSR Premerger Notification and Report Form 16 CFR Parts 801-803—Hart-Scott-Rodino Coverage, Exemption, and Transmittal Rules,…
Learn more
BIO's Comments on FTC Merger Guidelines
Learn more
Testimony of John F. Crowley, Executive Chairman…
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.
Learn more